Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage

British Journal of Clinical Pharmacology

Volumn 65, Issue 3, 2008, Pages 317-325

  Gueorguieva, Ivelina ^a,b   Clark, Simon R ^a,c,d   McMahon, Catherine J ^c   Scarth, Sylvia ^c   Rothwell, Nancy J ^a   Tyrell, Pippa J ^c   Hopkins, Stephen J ^c   Rowland, Malcolm ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c HOPE HOSPITAL   (United Kingdom)

^d WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

CSF; Interleukin 1 receptor antagonist; Ischemia; Modelling; Patients; Pharmacokinetics; Subarachnoid haemmorage

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL INFECTION; HEMATEMESIS; HUMAN; MALE; PRIORITY JOURNAL; STEADY STATE; SUBARACHNOID HEMORRHAGE; URINARY TRACT INFECTION;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SUBARACHNOID HEMORRHAGE; TIME FACTORS;

EID: 39849105534     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03026.x     Document Type: Article

References (32)

1. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999 79 : 1432 516.
2. Ginsberg MD. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection. The 2002 Thomas Willis lecture. Stroke 2002 34 : 214 33.
3. Allan SM, Rothwell NJ. Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci 2003 358 : 1669 77.
4. Rothwell NJ, Loddick SA, Stroemer P. Interleukins and cerebral ischaemia. Int Rev Neurobiol 1997 40 : 281 98.
5. Rothwell NJ, Allan SM, Toulmond S. The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J Clin Invest 1997 100 : 2648 52.
6. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005 5 : 629 40.
7. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992 29 : 243 6.
8. Touzani O, Boutin H, Chuquet J, Rothwell NJ. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol 1999 100 : 203 15.
9. Fisher CJ, Dhainaut JA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Greenman RL. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomised, double blind, placebo controlled trial. JAMA 1994 271 : 1836 43.
10. Nuki G, Bresnihan B, Bear MB, McCabe D. Long term safety and maintenance of clinical improvement following treatment with Anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002 46 : 2838 46.
11. Emsley HCA, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, Tyrell PJ for the IL-1 ra in acute stroke investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol, Neurosurg, Psychiatry 2005 76 : 1366 72.
12. Martin D, Chinookoswong N, Miller G. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol 1994 130 : 362 7.
13. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996 138 : 206 13.
14. Gutierrez EG, Banks WA, Kastin AJ. Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier. J Neuroimmunol 1994 55 : 153 60.
15. Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev 2000 45 : 283 94.
16. Teasdale GM, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974 2 : 81 4.
17. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid haemorrhage visualised by computerized tomographic scanning. Neurosurgery 1981 6 : 1 9.
18. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Maryland State Med J 1965 61 5.
19. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988 19 : 604 7.
20. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003 74 : 85 94.
21. Al Kassab S, Skyhoj OT, Skriver EB. Blood-brain barrier integrity in patients with cerebral infarction investigated by computed tomography and serum-CSF-albumin. Acta Neurol Scand 1981 64 : 438 45.
22. Beal S, Sheiner LB. The NONMEM system. Am Stat 1980 34 : 118 9.
23. Beal S, Sheiner LB, eds. NONMEM Users Guides. University of California at San Fransisco : NONMEM Project Group, 1998.
24. Granowitz EV, Porat R, Mier JW, Pribble JP, Syiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992 4 : 353 60.
25. Clark SR, Stuart A, Rothwell JN. Peripheral administartion of interlukin-1 receptor antagonist (IL-1RA) reduces ischaemic brain damage in the rat. J Cerebral Flow Metab 2005 25 : S45.
26. Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth S, Georgiou R, Tyrell PJ, Hopkins SJ, Rothwell NJ. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J. Cerebral Flow Metab 2007 Epub ahead of print. doi: 10.1038/sj.jcbfm.9600537.
27. Verotta D, Sheiner LB. A general conceptual model for non steady-state pharmacokinetic/pharmacodynamic data (plus response and rejoinder). J Pharmacokin Biopharm 1995 23 : 1 10.
28. Kosteljanetz M. Cerebrospinal production in subarchnoid haemorrhage. Br J Neurosurg 1988 2 : 161 7.
29. Rapoport SI. Blood-Brain Barrier in Physiology and Medicine. New York : Raven Press, 1976.
30. Kandel ER, Schwartz JH, Jessell TM. Principles of Neural Science. New York : McGraw-Hill, 2000 : 1296 7.
31. Berne RM, Levy MN. Principles of Physiology. Boston : Mosby, 1990 : 66 7.
32. Luetmer P, Huston J, Friedman JA, Dixon GR, Petersen RC, Jack CR, MaccLelland RL, Ebersold MJ, Milhorat TH, Hodge CJ. Measuremnt of cerebrospinal fluid flow at the cerebral aqueduct by use of phase-contrast magnetic resonance imaging: technique validation and utility in diagnosing idiopathic normal pressure hydrocephalus. Neurosurgery 2002 50 : 534 43.